Galectin Therapeutics (GALT) AI Stock Analysis

• Market Cap: $193.44M
• Dividend Yield: N/A
• Average Volume (3M): 341.94K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.85
• Revenue Growth: N/A
• EPS Growth: 18.82%
• Country: US
• Employees: 15
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.13
• Shares Outstanding: 64,479,210
• 10 Day Avg. Volume: 287,288
• 30 Day Avg. Volume: 341,945
• PEG Ratio: -0.63
• Price to Book (P/B): -0.78
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -1.92
• Enterprise Value/Market Cap: 1.66
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: -14.56K
• Enterprise Value/Ebitda: -10.62
• 1Y Price Target: $11.00
• Price Target Upside: 92.64% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 46 Neutral
• Price Target: $3.00 ▼(-47.46% Downside)

The score is held down primarily by weak financial performance (no meaningful revenue, sizable losses, negative equity, and ongoing cash burn with rising debt). Technicals also remain bearish with the stock below major moving averages and negative MACD, despite near-oversold readings. Offsetting these risks, corporate updates around NAVIGATE results, FDA interactions, and insider funding are constructive but not enough to outweigh the current financial and technical headwinds.

Positive Factors

Promising NAVIGATE trial results

Phase 2b NAVIGATE results demonstrating antifibrotic benefit and a favorable safety profile materially strengthen belapectin's clinical proposition. Durable efficacy and tolerability raise the probability of a viable registration pathway and long-term commercial opportunity if pivotal trials confirm these signals.

Regulatory alignment with FDA

A written FDA Type C response indicating alignment on the target population reduces regulatory uncertainty and helps focus pivotal trial design. This structural clarity increases the likelihood of an acceptable registration strategy and conserves resources by narrowing endpoints and patient selection.

Insider financing extends runway

Chairman-backed convertible credit and maturity extensions materially extend cash runway, allowing the company to complete regulatory interactions and prepare for pivotal work. Insider support reduces immediate liquidity stress and preserves the ability to advance belapectin without urgent asset disposals.

Negative Factors

Weak balance sheet; negative equity

Severely negative equity and materially rising debt versus minimal assets signal accumulated losses and constrained financial flexibility. Over months this elevates refinancing and creditor risk, limits strategic options, and increases the probability of dilutive financings or restructuring if clinical progress stalls.

Persistent negative cash flow

Sustained negative operating and free cash flow forces ongoing reliance on external funding, which structurally limits the company's ability to scale R&D or commercial activities. This dependence raises dilution risk and could impair program continuity if financing access tightens.

No meaningful revenue; sustained losses

The company remains entirely development-stage with no durable revenue stream and large recurring losses. Long-term viability thus depends on achieving regulatory approval and successful commercialization of belapectin, making fundamentals highly binary and sensitive to clinical outcomes.

Galectin Therapeutics Business Overview & Revenue Model

Company Description

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis cirrhosis, as well as for the treatment of cancer. It also engages in developing GM-CT-01, which is in pre-clinical development stage for the treatment of cardiac and vascular fibrosis, as well as focuses on developing belapectin for the treatment of psoriasis, and lung and kidney fibrosis. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and development of small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.

How the Company Makes Money

Galectin Therapeutics primarily makes money through research and development collaborations, licensing agreements, and milestone payments related to its drug candidates. The company partners with larger pharmaceutical firms to advance the development and commercialization of its therapies, receiving payments for achieving specific research and development milestones. Additionally, Galectin Therapeutics may earn revenue through licensing its proprietary technology and intellectual property to other companies, which can include upfront payments, royalties, and other financial incentives contingent upon the successful commercialization of their drug candidates.

Galectin Therapeutics Financial Statement Overview

Summary

Financials are highly challenged: essentially no revenue, persistently large net losses (about -$47.0M in 2024; -$37.3M TTM), and ongoing negative operating/free cash flow (about -$41.8M in 2024; -$30.6M TTM). Balance-sheet risk is elevated with negative equity (about -$103.1M in 2024; -$125.3M TTM) and materially higher debt (~$122.3M TTM) versus a small asset base (~$12.9M TTM). A modest positive is improving cash burn in TTM versus 2024, but reliance on external funding remains high.

Income Statement

Results remain highly challenged: the company reported essentially no revenue across the annual periods provided, while losses have widened versus 2020–2021 (net loss of about -$47.0M in 2024 and -$37.3M in TTM (Trailing-Twelve-Months)). Gross profit is negative in every period shown, and profitability remains deeply negative, indicating ongoing reliance on external funding rather than operating earnings. A modest positive is that the TTM net loss is smaller than 2024, but overall the business has not demonstrated a durable revenue base or a clear path to profitability in the reported history.

Balance Sheet

The balance sheet is a key weakness: stockholders’ equity is negative in recent periods (about -$103.1M in 2024 and -$125.3M in TTM (Trailing-Twelve-Months)), which typically signals significant accumulated losses and reduced financial flexibility. Total debt has risen materially over time (from near-zero in 2020 to ~$106.2M in 2024 and ~$122.3M in TTM), increasing refinancing and dilution risk. Total assets are relatively small (roughly $12.9M in TTM), highlighting limited balance-sheet cushion versus obligations.

Cash Flow

Cash generation remains weak, with operating cash flow and free cash flow consistently negative (about -$41.8M in 2024 and -$30.6M in TTM (Trailing-Twelve-Months)). The burn rate appears to have improved in TTM versus 2024, which is a near-term positive, but free cash flow growth is still negative in the latest TTM period, suggesting cash outflows remain elevated. Overall, the company continues to depend on financing to fund operations.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	-22.00K	-37.00K	-33.00K	-32.00K	-41.00K	-36.00K
EBITDA	-30.17M	-41.47M	-38.24M	-37.71M	-30.00M	-23.34M
Net Income	-37.30M	-47.05M	-41.07M	-38.78M	-30.53M	-23.46M
Balance Sheet
Total Assets	12.87M	17.50M	28.20M	21.29M	41.83M	29.60M
Cash, Cash Equivalents and Short-Term Investments	11.53M	15.12M	25.66M	18.59M	39.65M	27.14M
Total Debt	122.31M	106.25M	71.81M	39.87M	29.06M	44.00K
Total Liabilities	138.17M	120.56M	88.44M	53.48M	39.21M	5.41M
Stockholders Equity	-125.30M	-103.07M	-60.24M	-32.19M	2.62M	24.19M
Cash Flow
Free Cash Flow	-30.62M	-41.77M	-32.97M	-31.06M	-24.31M	-20.60M
Operating Cash Flow	-30.62M	-41.77M	-32.97M	-31.06M	-24.31M	-20.60M
Investing Cash Flow	0.00	0.00	0.00	0.00	0.00	0.00
Financing Cash Flow	15.09M	31.23M	40.03M	10.00M	36.81M	263.00K

Galectin Therapeutics Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 5.71
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GALT, the sentiment is Neutral. The current price of 5.71 is above the 20-day moving average (MA) of 3.16, above the 50-day MA of 4.42, and above the 200-day MA of 3.63, indicating a neutral trend. The MACD of -0.36 indicates Negative momentum. The RSI at 43.78 is Neutral, neither overbought nor oversold. The STOCH value of 33.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for GALT.

Galectin Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
TECX	55 Neutral	$421.49M	-5.96	-32.21%	―	―	60.40%
JBIO	55 Neutral	$765.97M	-1.50	-50.23%	14.68%	―	89.16%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
OMER	50 Neutral	$830.95M	-5.86	―	―	―	12.32%
GALT	46 Neutral	$193.44M	-5.50	―	―	―	18.82%
VYGR	46 Neutral	$222.40M	-1.80	-46.09%	―	-80.88%	-388.61%
TNYA	43 Neutral	$195.25M	-1.16	-96.44%	―	―	46.68%

Galectin Therapeutics Corporate Events

Galectin Therapeutics Approves Retention Bonuses for Key Executives

On January 16, 2026, Galectin Therapeutics’ board of directors, acting on the recommendation of its compensation committee, approved cash retention bonuses for two key executives: a $300,000 bonus for Chief Medical Officer Dr. Khurram Jamil and a $150,000 bonus for Chief Financial Officer Jack Callicutt. The bonuses, structured to be paid in three equal installments on June 1, September 1, and December 1, 2026, must be repaid if either executive resigns without good reason or is terminated for cause before December 31, 2026, underscoring the company’s focus on retaining senior leadership through the end of that year.

The most recent analyst rating on (GALT) stock is a Hold with a $3.00 price target. To see the full list of analyst forecasts on Galectin Therapeutics stock, see the GALT Stock Forecast page.

Galectin Therapeutics announces board resignation of Marc Rubin

On January 10, 2026, Galectin Therapeutics, Inc. announced that Marc Rubin resigned from its Board of Directors. The company specified that Rubin’s departure did not stem from any disagreement regarding its operations, policies or practices, suggesting no immediate disruption to governance or strategic direction for stakeholders.

The most recent analyst rating on (GALT) stock is a Hold with a $4.00 price target. To see the full list of analyst forecasts on Galectin Therapeutics stock, see the GALT Stock Forecast page.

Galectin Advances Belapectin Program, Secures New Insider Financing

On December 19, 2025, Galectin Therapeutics reported that the U.S. Food and Drug Administration provided a written response to the company’s Type C meeting request on the development program for belapectin, leading the company to believe there is regulatory alignment on the proposed patient population for a future registration trial in MASH cirrhosis. The company plans a follow-up Type C meeting to finalize remaining trial design details and to present new biomarker data, viewing this interaction as a key step toward a pivotal Phase 3 study and an opportunity to integrate input from external key opinion leaders, which it sees as important for advancing belapectin’s clinical strategy. Separately on December 19, 2025, Galectin Therapeutics entered into a new unsecured, convertible line of credit of up to $10 million with its chairman, Richard E. Uihlein, and extended the maturity of all his existing convertible credit lines and notes to June 30, 2027, a move that, together with existing cash, is expected to fund operations through at least March 2027 and underscores continued insider financial support as the company progresses its late-stage liver disease program.

The most recent analyst rating on (GALT) stock is a Buy with a $11.00 price target. To see the full list of analyst forecasts on Galectin Therapeutics stock, see the GALT Stock Forecast page.

Galectin Therapeutics Holds 2025 Annual Stockholders Meeting

At the 2025 Annual Meeting of Stockholders on December 3, 2025, Galectin Therapeutics‘ stockholders elected the nominated directors and approved a non-binding advisory resolution on executive compensation. They also ratified Cherry Bekaert LLP as the independent registered public accounting firm for the year ending December 31, 2025. The board decided to conduct advisory votes on executive compensation every three years.

The most recent analyst rating on (GALT) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on Galectin Therapeutics stock, see the GALT Stock Forecast page.

Galectin Therapeutics Reveals Promising NAVIGATE Trial Results

On December 3, 2025, Galectin Therapeutics presented compelling results from its NAVIGATE trial at its Annual Meeting of Stockholders. The trial focused on belapectin’s efficacy in treating MASH cirrhosis and portal hypertension, showing significant benefits in reducing liver stiffness and varices compared to placebo. The company highlighted the trial’s adaptive design and the decision to unblind data in 2024, which led to extensive data analysis throughout 2025. Key findings included belapectin’s impact on fibrosis and inflammation markers, with no drug-related serious adverse events reported. The results reinforce belapectin’s potential to change the treatment landscape for patients with no FDA-approved therapy, and Galectin is anticipating FDA feedback and exploring strategic opportunities to maximize program value.

The most recent analyst rating on (GALT) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on Galectin Therapeutics stock, see the GALT Stock Forecast page.

Galectin Therapeutics Presents Promising NAVIGATE Trial Results

On November 10, 2025, Galectin Therapeutics announced the presentation of its NAVIGATE trial results at the AASLD 2025 Annual Meeting. The Phase 2b trial evaluated belapectin, a galectin-3 inhibitor, in patients with compensated MASH cirrhosis and portal hypertension. The results demonstrated belapectin’s potential as a disease-modifying therapy, showing significant antifibrotic effects and a reduction in the incidence of new varices compared to placebo. These findings suggest a promising therapeutic option for patients with limited treatment choices, and the company is focused on advancing regulatory discussions and strategic partnerships to further develop belapectin.

The most recent analyst rating on (GALT) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on Galectin Therapeutics stock, see the GALT Stock Forecast page.